In Reply Dr Romanos and colleagues suggest that we included 5 trials in our Cochrane review1 that should have been excluded. We disagree. The 4 trials they state used active controls actually used these cointerventions similarly in both groups (ie, the methylphenidate and the control groups). Such trials should be included according to our protocol.1
Storebø OJ, Simonsen E, Gluud C. Methylphenidate for Attention-Deficit/Hyperactivity Disorder—Reply. JAMA. 2016;316(9):995. doi:10.1001/jama.2016.10300
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: